真实世界登记研究中因果推断方法评估生存差异与随机临床试验结果的实证比较
该实证研究基于大型观察性登记数据集,比较假设符合试验条件的患者与不符合条件患者在冠状动脉旁路移植术(CABG)和经皮冠状动脉介入治疗(PCI)下的生存轨迹,并探索因果推断方法的影响。结果显示32.5%的患者符合同期随机对照试验(RCT)条件,治疗选择存在偏倚,不同方法学途径结论一致。符合试验条件患者生存至少边际优于不符合者,治疗比较因疾病严重程度而异。
要点
- 真实世界登记中仅32.5%患者符合同期RCT条件,提示RCT纳入高度选择人群。
- PCI与CABG患者倾向性评分分布不同,存在治疗选择偏倚。
- 符合试验条件的三支病变患者CABG似有轻微优势,其余无治疗差异。
核心结论
- RCT纳入高度选择人群,本分析结果与RCT总体一致但弱于主要登记研究发现。
研究设计与样本
- 基于大型观察性登记数据集的实证研究,估计假设符合试验条件与不符合条件患者在CABG和PCI下的生存轨迹。
- 探索逆概率治疗加权与最优完全倾向性匹配两种因果推断方法,以及多重插补倾向性评分的「跨数据集」与「数据集内」合并方式对结果的影响。
主要发现
- 在PCI/CABG多支病变患者登记人群中,32.5%符合同期RCT条件。
- PCI与CABG患者倾向性评分分布不同,提示治疗选择偏倚。
- 不同方法学途径未导致不同结论。
- 符合试验条件患者生存至少边际优于不符合条件患者。
- 治疗比较因疾病严重程度而异:符合试验条件的三支病变患者CABG似有轻微优势,不符合条件的二支病变患者CABG亦似有轻微优势,其余无治疗差异。
临床怎么用
- 解读真实世界证据时应考虑试验资格对生存轨迹的影响及治疗选择偏倚。
- 因果推断方法选择(逆概率治疗加权 vs 最优完全倾向性匹配)在本研究中未改变结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
With heighted interest in causal inference based on real-world evidence, this empirical study sought to understand differences between the results of observational analyses and long-term randomized clinical trials. We hypothesized that patients deemed "eligible" for clinical trials would follow a different survival trajectory from those deemed "ineligible" and that this factor could partially explain results. In a large observational registry dataset, we estimated separate survival trajectories for hypothetically trial-eligible vs ineligible patients under both coronary artery bypass surgery (CABG) and percutaneous coronary intervention (PCI). We also explored whether results would depend on the causal inference method (inverse probability of treatment weighting vs optimal full propensity matching) or the approach to combine propensity scores from multiple imputations (the "across" vs "within" approaches). We found that, in this registry population of PCI/CABG multivessel patients, 32.5% would have been eligible for contemporaneous RCTs, suggesting that RCTs enroll selected populations. Additionally, we found treatment selection bias with different distributions of propensity scores between PCI and CABG patients. The different methodological approaches did not result in different conclusions. Overall, trial-eligible patients appeared to demonstrate at least marginally better survival than ineligible patients. Treatment comparisons by eligibility depended on disease severity. Among trial-eligible three-vessel diseased and trial-ineligible two-vessel diseased patients, CABG appeared to have at least a slight advantage with no treatment difference otherwise. In conclusion, our analyses suggest that RCTs enroll highly selected populations, and our findings are generally consistent with RCTs but less pronounced than major registry findings.
引用
- Lee HJ, Wong JB, Jia B, et al. Empirical use of causal inference methods to evaluate survival differences in a real-world registry vs those found in randomized clinical trials. Stat Med. 2020. PMID: 32643219. doi:10.1002/sim.8581
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。